Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales
Purpose: The infection of carbapenem-resistant Enterobacterales (CRE) has become a major clinical and healthcare problem worldwide. The screening methods of CRE have been extensively developed but still need improving [e.g., tests with accurate and simple minimum inhibitory (MICs)]. In this study, t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.643194/full |
| _version_ | 1818850922624712704 |
|---|---|
| author | Jingjia Zhang Peiyao Jia Peiyao Jia Ying Zhu Ying Zhu Ge Zhang Yingchun Xu Qiwen Yang |
| author_facet | Jingjia Zhang Peiyao Jia Peiyao Jia Ying Zhu Ying Zhu Ge Zhang Yingchun Xu Qiwen Yang |
| author_sort | Jingjia Zhang |
| collection | DOAJ |
| description | Purpose: The infection of carbapenem-resistant Enterobacterales (CRE) has become a major clinical and healthcare problem worldwide. The screening methods of CRE have been extensively developed but still need improving [e.g., tests with accurate and simple minimum inhibitory (MICs)]. In this study, the performance of the BD Phoenix NMIC-413 AST panel was evaluated against clinical CRE and carbapenem-susceptible Enterobacterales (CSE) in China. The panel was first evaluated in the Chinese clinical lab.Methods: Antimicrobial susceptibility testing of 303 clinical Enterobacterales isolates were conducted by broth microdilution (BMD), Phoenix NMIC-413 AST panel, and disk diffusion method for imipenem, ertapenem, and meropenem. Considering BMD is a gold standard, essential agreement (EA), categorical agreement (CA), minor error (MIE), major error (ME), and very major error (VME) were determined according to CLSI guidelines. CA and EA > 90%, ME <3%, and VME <1.5% were considered as acceptable criteria. Polymerase chain reaction and sanger sequencing were performed to determine the β-lactamase genotypes of CRE isolates.Results: Three hundred and three isolates included 195 CREs and 108 CSEs were enrolled according to the BMD-MIC values of three carbapenems. Tested CREs showing 100 blaKPC−2-positive organisms, 31 blaIMP-positive organisms, 28 blaNDM-positive organisms, 5 blaVIM-positive organisms, 2 both blaIMP and blaVIM-positive organisms, 2 blaOXA−48-positive organisms, and 27 isolates without carbapenemase genes. For the Phoenix NMIC-413 method, CA and EA rates >93%, MIE rates <5%, ME rates <1.75%, and VME rates were 0%, across the three drugs. For the disk diffusion method, the CA rates for three drugs were all >93%, while the MIE and ME rates were all <5 and <3%, respectively. VME rate was 3.28% for imipenem, exceeded the cut-off value specified by CLSI M52, 0 and 0.56% for ertapenem and meropenem, separately.Conclusion: Based on the genomic data, the detection of CRE and CSE was more reliable using the BD Phoenix NMIC-413 panel compared to the BMD and disk approaches. Therefore, our study supports the use of BD Phoenix NMIC-413 panel as a suitable alternative to BMD for the detection of carbapenem resistant isolates in a clinical setting. |
| first_indexed | 2024-12-19T06:56:50Z |
| format | Article |
| id | doaj.art-e86b94f887d84df4a57c0282ae6a6dde |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-19T06:56:50Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-e86b94f887d84df4a57c0282ae6a6dde2022-12-21T20:31:31ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-04-01810.3389/fmed.2021.643194643194Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible EnterobacteralesJingjia Zhang0Peiyao Jia1Peiyao Jia2Ying Zhu3Ying Zhu4Ge Zhang5Yingchun Xu6Qiwen Yang7Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaGraduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaGraduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, ChinaPurpose: The infection of carbapenem-resistant Enterobacterales (CRE) has become a major clinical and healthcare problem worldwide. The screening methods of CRE have been extensively developed but still need improving [e.g., tests with accurate and simple minimum inhibitory (MICs)]. In this study, the performance of the BD Phoenix NMIC-413 AST panel was evaluated against clinical CRE and carbapenem-susceptible Enterobacterales (CSE) in China. The panel was first evaluated in the Chinese clinical lab.Methods: Antimicrobial susceptibility testing of 303 clinical Enterobacterales isolates were conducted by broth microdilution (BMD), Phoenix NMIC-413 AST panel, and disk diffusion method for imipenem, ertapenem, and meropenem. Considering BMD is a gold standard, essential agreement (EA), categorical agreement (CA), minor error (MIE), major error (ME), and very major error (VME) were determined according to CLSI guidelines. CA and EA > 90%, ME <3%, and VME <1.5% were considered as acceptable criteria. Polymerase chain reaction and sanger sequencing were performed to determine the β-lactamase genotypes of CRE isolates.Results: Three hundred and three isolates included 195 CREs and 108 CSEs were enrolled according to the BMD-MIC values of three carbapenems. Tested CREs showing 100 blaKPC−2-positive organisms, 31 blaIMP-positive organisms, 28 blaNDM-positive organisms, 5 blaVIM-positive organisms, 2 both blaIMP and blaVIM-positive organisms, 2 blaOXA−48-positive organisms, and 27 isolates without carbapenemase genes. For the Phoenix NMIC-413 method, CA and EA rates >93%, MIE rates <5%, ME rates <1.75%, and VME rates were 0%, across the three drugs. For the disk diffusion method, the CA rates for three drugs were all >93%, while the MIE and ME rates were all <5 and <3%, respectively. VME rate was 3.28% for imipenem, exceeded the cut-off value specified by CLSI M52, 0 and 0.56% for ertapenem and meropenem, separately.Conclusion: Based on the genomic data, the detection of CRE and CSE was more reliable using the BD Phoenix NMIC-413 panel compared to the BMD and disk approaches. Therefore, our study supports the use of BD Phoenix NMIC-413 panel as a suitable alternative to BMD for the detection of carbapenem resistant isolates in a clinical setting.https://www.frontiersin.org/articles/10.3389/fmed.2021.643194/fullBD Phoenix NMIC-413CREbroth microdilutiondisk diffusionevaluation |
| spellingShingle | Jingjia Zhang Peiyao Jia Peiyao Jia Ying Zhu Ying Zhu Ge Zhang Yingchun Xu Qiwen Yang Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales Frontiers in Medicine BD Phoenix NMIC-413 CRE broth microdilution disk diffusion evaluation |
| title | Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales |
| title_full | Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales |
| title_fullStr | Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales |
| title_full_unstemmed | Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales |
| title_short | Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales |
| title_sort | performance evaluation of bd phoenix nmic 413 antimicrobial susceptibility testing panel for imipenem meropenem and ertapenem against clinical carbapenem resistant and carbapenem susceptible enterobacterales |
| topic | BD Phoenix NMIC-413 CRE broth microdilution disk diffusion evaluation |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.643194/full |
| work_keys_str_mv | AT jingjiazhang performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT peiyaojia performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT peiyaojia performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT yingzhu performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT yingzhu performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT gezhang performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT yingchunxu performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales AT qiwenyang performanceevaluationofbdphoenixnmic413antimicrobialsusceptibilitytestingpanelforimipenemmeropenemandertapenemagainstclinicalcarbapenemresistantandcarbapenemsusceptibleenterobacterales |